7.44
price up icon0.13%   0.01
after-market 시간 외 거래: 7.44
loading
전일 마감가:
$7.43
열려 있는:
$7.37
하루 거래량:
734.56K
Relative Volume:
0.47
시가총액:
$454.96M
수익:
$91.06M
순이익/손실:
$-503.14M
주가수익비율:
-0.8868
EPS:
-8.39
순현금흐름:
$-424.74M
1주 성능:
+0.54%
1개월 성능:
-8.15%
6개월 성능:
-4.49%
1년 성능:
-44.19%
1일 변동 폭
Value
$7.27
$7.64
1주일 범위
Value
$7.27
$7.64
52주 변동 폭
Value
$4.62
$14.97

Sage Therapeutics Inc Stock (SAGE) Company Profile

Name
명칭
Sage Therapeutics Inc
Name
전화
617-299-8380
Name
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
직원
487
Name
트위터
@SageBiotech
Name
다음 수익 날짜
2025-02-11
Name
최신 SEC 제출 서류
Name
SAGE's Discussions on Twitter

SAGE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SAGE
Sage Therapeutics Inc
7.44 454.96M 91.06M -503.14M -424.74M -8.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-11 재개 BofA Securities Underperform
2024-11-21 업그레이드 RBC Capital Mkts Underperform → Sector Perform
2024-10-10 재개 Raymond James Mkt Perform
2024-10-04 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2024-07-30 다운그레이드 TD Cowen Buy → Hold
2024-07-25 다운그레이드 JP Morgan Overweight → Neutral
2024-05-29 개시 Citigroup Sell
2024-05-29 개시 Robert W. Baird Neutral
2024-04-17 다운그레이드 BofA Securities Neutral → Underperform
2023-12-12 개시 Deutsche Bank Hold
2023-08-08 다운그레이드 Canaccord Genuity Buy → Hold
2023-08-08 다운그레이드 Goldman Buy → Neutral
2023-08-08 다운그레이드 Needham Buy → Hold
2023-08-07 다운그레이드 BofA Securities Buy → Neutral
2023-08-07 다운그레이드 Oppenheimer Outperform → Perform
2023-08-07 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-08-07 다운그레이드 Stifel Buy → Hold
2023-08-07 다운그레이드 Wedbush Outperform → Neutral
2023-07-27 개시 Scotiabank Sector Outperform
2023-03-13 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2023-01-03 다운그레이드 Guggenheim Buy → Neutral
2022-11-01 개시 Loop Capital Hold
2022-03-31 개시 Berenberg Hold
2021-11-02 업그레이드 Guggenheim Neutral → Buy
2021-10-19 재개 Morgan Stanley Equal-Weight
2021-10-07 다운그레이드 Jefferies Buy → Hold
2021-09-23 개시 Needham Buy
2021-06-16 다운그레이드 Citigroup Buy → Neutral
2021-04-07 개시 Piper Sandler Overweight
2021-02-26 다운그레이드 Mizuho Buy → Neutral
2021-02-25 재확인 H.C. Wainwright Neutral
2021-02-02 재개 Raymond James Mkt Perform
2021-01-22 다운그레이드 BMO Capital Markets Outperform → Market Perform
2021-01-04 업그레이드 Guggenheim Neutral → Buy
2021-01-04 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2020-12-04 업그레이드 Mizuho Neutral → Buy
2020-12-01 다운그레이드 Raymond James Outperform → Mkt Perform
2020-11-16 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-11-06 재확인 H.C. Wainwright Neutral
2020-09-11 업그레이드 Wedbush Neutral → Outperform
2020-08-10 업그레이드 Raymond James Mkt Perform → Outperform
2020-05-08 다운그레이드 Wedbush Outperform → Neutral
2020-04-08 다운그레이드 Guggenheim Buy → Neutral
2020-03-18 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2020-03-06 개시 Citigroup Buy
2020-02-28 재확인 H.C. Wainwright Neutral
2020-02-06 개시 Mizuho Neutral
2019-12-06 재확인 RBC Capital Mkts Outperform
2019-12-05 재확인 Guggenheim Buy
2019-12-05 다운그레이드 SunTrust Buy → Hold
2019-10-30 개시 H.C. Wainwright Neutral
2019-05-23 개시 Wedbush Outperform
2019-04-25 개시 Jefferies Buy
2018-12-14 개시 Wolfe Research Outperform
2018-10-11 개시 Oppenheimer Outperform
모두보기

Sage Therapeutics Inc 주식(SAGE)의 최신 뉴스

pulisher
Apr 20, 2025

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com

Apr 20, 2025
pulisher
Apr 19, 2025

Lobbying Update: $50,000 of SAGE THERAPEUTICS lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 19, 2025

Q1 EPS Estimates for Sage Therapeutics Increased by Wedbush - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Q1 Earnings Forecast for SAGE Issued By Wedbush - Defense World

Apr 18, 2025
pulisher
Apr 18, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 18, 2025
pulisher
Apr 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect - markets.businessinsider.com

Apr 17, 2025
pulisher
Apr 15, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - markets.businessinsider.com

Apr 15, 2025
pulisher
Apr 15, 2025

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 | SAGE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Corebridge Financial Inc. Sells 2,050 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 13, 2025

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Apr 13, 2025
pulisher
Apr 13, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Position Lessened by American Century Companies Inc. - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Buys New Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc.SAGE - Business Wire

Apr 11, 2025
pulisher
Apr 10, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com

Apr 10, 2025
pulisher
Apr 10, 2025

SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces - GlobeNewswire

Apr 10, 2025
pulisher
Apr 10, 2025

SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. - Bluefield Daily Telegraph

Apr 10, 2025
pulisher
Apr 09, 2025

Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story - Seeking Alpha

Apr 09, 2025
pulisher
Apr 09, 2025

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag - Seeking Alpha

Apr 09, 2025
pulisher
Apr 09, 2025

Class Action Filed Against Sage Therapeutics, Inc. (SAGE)October 28, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Apr 09, 2025
pulisher
Apr 08, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation - markets.businessinsider.com

Apr 08, 2025
pulisher
Apr 06, 2025

(SAGE) Proactive Strategies - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 06, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out - markets.businessinsider.com

Apr 06, 2025
pulisher
Apr 04, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Thrivent Financial for Lutherans - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com

Apr 03, 2025
pulisher
Apr 03, 2025

RBC Raises Price Target on SAGE Therapeutics to $7 From $6, Keeps Sector Perform, Speculative Risk - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Teacher Retirement System of Texas - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

SAGE LAWSUIT ALERT: Levi & Korsinsky Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com

Apr 01, 2025
pulisher
Mar 30, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect - markets.businessinsider.com

Mar 30, 2025
pulisher
Mar 29, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

SAGE THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc.SAGE - The Malaysian Reserve

Mar 28, 2025
pulisher
Mar 28, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Rating of “Hold” by Analysts - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - Markets Insider

Mar 27, 2025
pulisher
Mar 27, 2025

Sage Therapeutics ($SAGE) Failed Drug Launch and Misleading FDA Guidance Case - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

How To Trade (SAGE) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Bank of New York Mellon Corp Has $931,000 Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - Markets Insider

Mar 25, 2025
pulisher
Mar 22, 2025

Amundi Invests $166,000 in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Mar 22, 2025
pulisher
Mar 19, 2025

Investors who hold shares of Sage Therapeutics, Inc. (NASDAQ: - openPR.com

Mar 19, 2025
pulisher
Mar 18, 2025

US Bancorp DE Acquires 2,268 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Notice to Long-Term Shareholders of Fluence Energy, Inc. - GlobeNewswire

Mar 17, 2025
pulisher
Mar 16, 2025

Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on You - The Globe and Mail

Mar 15, 2025
pulisher
Mar 14, 2025

Notice to Long-Term Shareholders of Mercury Systems, Inc. - GlobeNewswire

Mar 14, 2025
pulisher
Mar 14, 2025

Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims - Morningstar

Mar 14, 2025
pulisher
Mar 14, 2025

Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.

Mar 14, 2025
pulisher
Mar 13, 2025

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Be - TradingView

Mar 13, 2025

Sage Therapeutics Inc (SAGE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
자본화:     |  볼륨(24시간):